Last update 04 Sep 2026

HY-1608

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
HY-1608
Target
OOR x μ opioid receptor
Action
agonists
Mechanism
OOR agonists(Nociceptin receptor agonists), μ opioid receptor agonists(Mu opioid receptor agonists)
Therapeutic Areas
Nervous System DiseasesOther Diseases
Active Indication
Pain, PostoperativeCancer PainDepressive Disorder, Treatment-Resistant
Inactive Indication-
Originator Organization
Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.
Active Organization
Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with HY-1608
CTR20252836
/ RecruitingPhase 2
评价HY-1608注射液用于腹部手术受试者术后镇痛有效性及安全性的多中心、随机、双盲、安慰剂及阳性药对照的II期临床试验
[Translation] A multicenter, randomized, double-blind, placebo- and active drug-controlled Phase II clinical trial to evaluate the efficacy and safety of HY-1608 injection for postoperative analgesia in subjects undergoing abdominal surgery
CTR20244082
/ CompletedPhase 1
单中心、随机、双盲、安慰剂对照评价HY-1608注射液在中国健康成年志愿者中单次给药的安全性、耐受性、药代动力学特征的I期临床试验
[Translation] A single-center, randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of HY-1608 injection in healthy adult volunteers in China
100 Clinical Results associated with HY-1608
Login to view more data
100 Translational Medicine associated with HY-1608
Login to view more data
100 Patents (Medical) associated with HY-1608
Login to view more data
100 Deals associated with HY-1608
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pain, PostoperativePhase 2
China
Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.
25 Aug 2025
Cancer PainPreclinical
China
Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.
01 Sep 2026
Depressive Disorder, Treatment-ResistantPreclinical
China
Beijing Junke Huayuan Pharmaceutical Technology Co., Ltd.
01 Sep 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free